From the Department of Anesthesiology, Hospital for Special Surgery, New York, New York.
Department of Anesthesiology, Weill Cornell Medicine, New York, New York.
Anesth Analg. 2024 Jan 1;138(1):31-41. doi: 10.1213/ANE.0000000000006301. Epub 2023 Dec 15.
Federal and state laws in the United States governing the use of cannabis are rapidly evolving. Under federal law, marijuana and its derivatives remain schedule I, defined as substances having no currently accepted medical use and a high potential for abuse. Hemp and its derivatives, in contrast, have been removed from schedule I. At the state level, a majority of states have passed laws legalizing cannabis in some form, although these laws vary from state to state in terms of the extent to which use is permitted, approved medical uses, and the types of regulation placed on commercial activity and quality control. This inconsistency has contributed to uncertainty among medical providers and their patients. In this review, we provide a brief account of the evolution and current state of federal and state laws and regulatory agencies involved in overseeing medical cannabis use in the United States.
美国联邦和州法律对大麻的使用规定正在迅速演变。根据联邦法律,大麻及其衍生物仍被归类为附表 I,被定义为没有当前被认可的医疗用途且具有高度滥用潜力的物质。相比之下,大麻的纤维及其衍生物已从附表 I 中移除。在州一级,大多数州已经以某种形式通过了大麻合法化的法律,尽管这些法律在允许使用的程度、批准的医疗用途以及对商业活动和质量控制的监管类型方面因州而异。这种不一致性导致医疗提供者及其患者感到不确定。在这篇综述中,我们简要介绍了美国联邦和州法律以及监管机构在监督医用大麻使用方面的演变和现状。